Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
OPEN Annals of the rheumatic diseases | 7 Mar 2014
A Kavanaugh, PJ Mease, JJ Gomez-Reino, AO Adebajo, J Wollenhaupt, DD Gladman, E Lespessailles, S Hall, M Hochfeld, C Hu, D Hough, RM Stevens and G Schett
Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy.
* Data courtesy of Altmetric.com